No long-term survival benefit with sustained-release 5-fluorouracil implants in patients with stages II and III gastric cancer

Table 3 Univariate and multivariate Cox analysis of patients

	Univariate analysis			Multivariate analysis
Characteristics	HR	95%CI	P value	HR	95%CI	P value
Gender
Male	Reference
Female	1.058	0.712-1.572	0.781
Age, yr
< 60	Reference
≥ 60	1.03	0.717-1.481	0.872
Neoadjuvant therapy
No	Reference
Yes	2.188	1.448-3.306	< 0.001	2.118	1.194-3.759	0.01
BMI
Normal < 24	Reference
Abnormal ≥ 24	0.752	0.516-1.098	0.14
Cardiovascular disease
No	Reference
Yes	0.943	0.606-1.467	0.794
Diabetes
No	Reference
Yes	0.891	0.479-1.658	0.715
Drug administration
No	Reference
Yes	1.052	0.731-1.513	0.786
Resection type
Total gastrectomy	Reference
Partial gastrectomy	0.558	0.387-0.804	0.002	0.663	0.428-1.027	0.066
Borrmann classification
Superficial type, Type I and II	Reference
Type III and IV	2.203	1.378-3.522	0.001	1.562	0.951-2.566	0.078
Lauren classification
Intestinal type	Reference
Others	1.158	0.762-1.762	0.492
Differentiation type
Low	Reference
Others	0.874	0.535-1.430	0.593
TNM stage
Stage II	Reference
Stage III	3.12	1.977-4.926	< 0.001	1.315	0.561-3.084	0.528
T stage
T1 and T2	Reference
T3 and T4	3.382	1.649-6.937	0.001	1.9	0.777-4.645	0.159
N stage
N0 and N1	Reference
N2 and N3	2.516	1.636-3.869	< 0.001	2.224	1.082-4.572	0.03
Signet-ring cell carcinoma
Yes	Reference
No	1.188	0.736-1.916	0.481
Nerve invasion
No	Reference
Yes	1.703	0.938-3.093	0.08
Vascular tumor thrombus
No	Reference
Yes	1.099	0.701-1.722	0.681

HR: Hazard ratio; CI: Confidence interval; BMI: Body mass index.